Lupin receives USFDA approval to market generic antifungal tablets

25 Oct 2023 , 02:12 PM

Lupin Ltd, a pharma major, announced on Monday that it has gained clearance from the United States Food and Drug Administration (USFDA) to commercialise its generic Fluconazole pills, which are used to treat fungal infections.

Lupin stated in a regulatory filing that the US Food and Drug Administration (USFDA) approved Fluconazole tablets in strengths of 50 mg, 100 mg, 150 mg, and 200 mg for an abbreviated new drug application.

These are the generic versions of Pfizer Inc’s Diflucan pills, 50 mg, 100 mg, 150 mg, and 200 mg, it noted.

Fluconazole Tablets had a projected annual sales of USD 43 million in the United States, according to Lupin, citing IQVIA MAT July 2023 data.

At around 1.50 PM, Lupin was trading 2.05% lower at Rs 1,144 per piece, against the previous close of Rs 1,168 on NSE. The counter touched an intraday high and low of Rs 1,190 and Rs 1,135.25, respectively.

For feedback and suggestions, write to us at [e-mail]